title: Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
authors.affiliation: Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA. ebrass@ucla.edu
authors.forename: Eric P
authors.initials: EP
authors.lastname: Brass
mesh_terms: D026683:Advisory Committees; D017277:Drug Approval; D006801:Humans; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration